Huntington’s Disease Market Anticipates Impressive Growth Trajectory Through 2032 – Asserts DelveInsight | Annexon, Celon Pharma, EIP Pharma, Luye Pharma, Medesis, Neurimmune, Novartis, Prilenia

Huntington’s Disease Market Anticipates Impressive Growth Trajectory Through 2032 - Asserts DelveInsight | Annexon, Celon Pharma, EIP Pharma, Luye Pharma, Medesis, Neurimmune, Novartis, Prilenia
Delveinsight Business Research LLP
As per DelveInsight, the Huntington’s Disease Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases of Huntington’s Disease and the launch of new therapies in the market.

DelveInsight’s “Huntington’s Disease Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Huntington’s Disease market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Huntington’s Disease drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Huntington’s Disease treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Huntington’s Disease: An Overview

Huntington’s disease (HD) is an incurable, rare genetic, progressive neurodegenerative disorder that causes brain cells, termed as neurons, to die in several areas of the brain, comprising those that help control voluntary (intentional) movement. The symptoms usually start at 30 to 50 years of age, but can begin earlier than this (juvenile Huntington’s disease) or much later.

Huntington’s disease is inherited as an autosomal dominant trait. In dominant disorders, a single copy of the disease gene (received from either the mother or father) will be expressed “dominating” the other normal gene, resulting in the appearance of the disease. Huntington’s disease is caused by variations (mutations) of a gene (huntingtin) that is located on the short arm (p) of chromosome 4 (4p16.3).

Currently, the treatment strategies include the usage of many medications to treat specific symptoms such as medicines for depression, mood swings, and involuntary/abnormal movements and behaviors. Depression and suicide are more common among affected people, so caregivers should monitor for associated symptoms and seek help if necessary. It becomes crucial for caregivers to watch symptoms closely and seek medical help immediately when issues or questions come up. As symptoms of the disease worsen, affected people need more assistance, supervision, and care.

Huntington’s Disease Market Key Facts

  • In 2021, the total market size of Huntington’s disease was USD 198.66 million, which is expected to rise during the study period (2019–2032).

  • The total market size of Huntington’s disease in the United States accounted for USD 187.06 million in 2021.

  • In EU5, the total market size of Huntington’s disease was USD 11.03 million in 2021.

  • In Japan, the total market size of Huntington’s disease was USD 0.57 million in 2021.

  • In the year 2021, the total number of prevalent cases of Huntington’s Disease was found to be 80,170 in the 7MM. In the 7MM, the most prevalent cases of Huntington’s Disease were found to be in the US, followed by Germany.

  • The US accounted for 22,387 diagnosed prevalent cases of Huntington’s disease in the year 2021.

Huntington’s Disease Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Huntington’s Disease pipeline therapies. It also thoroughly assesses the Huntington’s Disease market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the market trend for each marketed Huntington’s Disease drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Huntington’s Disease Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Huntington’s Disease epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Huntington’s Disease epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Huntington’s Disease Epidemiology, Segmented as –

  • Total prevalent cases of Huntington’s disease in the 7MM (2019–2032)

  • Total diagnosed prevalent cases of Huntington’s disease in the 7MM (2019–2032)

  • Total age group-specific cases of Huntington’s disease in the 7MM (2019–2032)

  • Total chorea-associated cases of Huntington’s disease in the 7MM (2019–2032)

  • Total treated cases of Huntington’s disease in the 7MM (2019–2032)

  • Total clinical stage-specific cases of Huntington’s disease in the 7MM (2019–2032)

Huntington’s Disease Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Huntington’s Disease market or expected to be launched during the study period. The analysis covers the Huntington’s Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares Huntington’s Disease drugs based on their sale and market share.

The report also covers the Huntington’s Disease pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Huntington’s Disease companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Huntington’s Disease Market Will Evolve and Grow by 2032 @

Key Developments in the Huntington’s Disease Therapeutics Market

  • On March 28, 2023, Prilenia Therapeutics B.V., announced that the last participant in PROOF-HD, a global Phase 3 study in Huntington’s disease (HD), has completed the last planned visit of the blinded treatment period, marking the completion of the main study. Almost all patients (98 percent) that were eligible elected to continue in the ongoing open-label extension of PROOF-HD. Topline results of the PROOF-HD study are expected in early Q2, 2023.

  • On April 3, 2023, Vico Therapeutics B.V., announced that the first patient has been dosed in a Phase 1/2a clinical study evaluating VO659 for the treatment of Huntington’s disease (HD), spinocerebellar ataxia type 1 (SCA1) and type 3 (SCA3). VO659 is an antisense oligonucleotide (ASO) investigational therapy designed to target the CAG repeat expansion that causes all nine known polyglutamine diseases including HD, SCA1, and SCA3.

Huntington’s Disease Companies Actively Working in the Therapeutics Market Include

Amsterdam Molecular Therapeutics, Annexon, Annexon Biosciences, Celon Pharma, EIP Pharma, Hope Biosciences, Luye Pharma Group, Medesis Pharma, Neurimmune Therapeutics, Neurocrine Biosciences, Novartis, Prilenia Therapeutics, Ionis Pharmaceuticals, PTC Therapeutics, Retrotope, SAGE Therapeutics, SOLA Biosciences, SOM Biotech, Stealth BioTherapeutics, Takeda, UniQure Biopharma, Vaccinex, Wave life sciences, and others.

Huntington’s Disease Therapies Covered in the Report Include:

  • AMT-130 (intra-striatal rAAV5-miHTT): UniQure Biopharma

  • ANX005: Annexon Biosciences

  • Ingrezza (Valbenazine/NBI-98854): Neurocrine Biosciences

  • Pepinemab (VX15/2503): Vaccinex

  • Pridopidine (ACR-16; Huntexil): Prilenia Therapeutics

  • Pridopidine: Prilenia Therapeutics

  • SAGE-718: SAGE Therapeutics

  • SOM3355/ Bevantolol: SOM Biotech

  • Tominersen: Ionis Pharmaceuticals

And many more

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Huntington’s Disease Competitive Intelligence Analysis

4. Huntington’s Disease Market Overview at a Glance

5. Huntington’s Disease Disease Background and Overview

6. Huntington’s Disease Patient Journey

7. Huntington’s Disease Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Huntington’s Disease Treatment Algorithm, Current Treatment, and Medical Practices

9. Huntington’s Disease Unmet Needs

10. Key Endpoints of Huntington’s Disease Treatment

11. Huntington’s Disease Marketed Therapies

12. Huntington’s Disease Emerging Drugs and Latest Therapeutic Advances

13. Huntington’s Disease Seven Major Market Analysis

14. Attribute Analysis

15. Huntington’s Disease Market Outlook (In US, EU5, and Japan)

16. Huntington’s Disease Companies Active in the Market

17. Huntington’s Disease Access and Reimbursement Overview

18. KOL Views on the Huntington’s Disease Market

19. Huntington’s Disease Market Drivers

20. Huntington’s Disease Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @


About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Elevating Cancer Care: DelveInsight’s specialized oncology consulting empowers with tailored guidance and forefront proficiency, enabling adept navigation of ever-evolving clinical, commercial, and regulatory landscapes. Explore further at Oncology Market Outlook

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States